Navigation Links
New protein linked to Alzheimer's disease

MANHASSET, NY -- After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease. The finding, reported in the June 14th issue of the Journal of Alzheimer's Disease, offers a new target for drug development that could stave off the pathological disease process.

Peter Davies, PhD, head of the Feinstein Institute's Litwin-Zucker Center for Research in Alzheimer's Disease, became interested in c-Abl when he found that the protein was part of the plaques and tangles that crowd the brains of Alzheimer's patients. The protein c-Abl is a tyrosine kinase involved in cell differentiation, cell division and cell adhesion. In patients with chronic myeloid leukemia (CML), c-Abl is turned up in B cells. Inhibiting c-Abl with the cancer drug Gleevec prevents cell division. There was quite a lot known about c-Abl when Dr. Davies began thinking about its possible role in Alzheimer's. He was looking at kinases that phosphorylate tau, the protein that accumulates inside of the neurons during the disease process.

Dr. Davies questioned whether activated c-Abl turned on the cell cycle and could kill adult cells. He designed the study to test this idea and found that turning on the cell cycle in adult brain damages the cells. In their current study, the investigators devised a clever way to activate c-Abl in neurons of normal adult mice. They turned on human c-Abl genes in two different regions the hippocampus and the neocortex in adult mice and discovered abundant cell death, especially in the hippocampus. "You don't even need to count, you can just look and see holes in the cell layers of the hippocampus," said Dr. Davies. "It is stunning. Even before the neurons die, there is florid inflammation."

He said that the animal model is ideal for testing the benefit of drugs that turn off c-Abl. While Gleevec works in CML, it does not cross the blood-brain barrier so it would not be useful. Dr. Davies and his colleagues are looking for other drugs that inhibit c-Abl and can get into the brain. "We have a great model to test compounds for Alzheimer's disease. Will regulating c-Abl make a difference for patients? We won't know unless we try it in double blind clinical trials."

The researchers are now working to understand the mechanism of cell death. They are also investigating why males die considerably sooner than females 12 to 15 weeks compared to 24 to 26 weeks. "It is an incredibly interesting model," said Dr. Davies. "If c-Abl is important we can learn how it works."


Contact: Jamie Talan
North Shore-Long Island Jewish (LIJ) Health System

Related medicine news :

1. New and Delicious, Almond Butter Filled, Cookie Bites With 35.7% Protein to Help Manage Weight and Build Muscle
2. Research highlights role of protein pair in obesity regulation
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
5. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
6. Protein Appears Key to Intestinal Balance
7. SIBLING proteins may predict oral cancer
8. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
9. Cells of aggressive leukemia hijack normal protein to grow
10. Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants
11. Proteins May Predict Spread of Colon Cancer
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continue the expansion of the company’s growing product line of food safety and ... tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December ... a fixed price per sprint agile development contract to support the National Geospatial-Intelligence ... five years, provides software engineering, infrastructure, as well as operations and sustainment support ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VERONA, Va. , Dec. 1, 2015 /PRNewswire/ ... today unveiled a new corporate logo and brand ... in the design and engineering of bladed products ... --> --> Serving ... fiber, glass, and auto glass equipment, AccuTEC,s product ...
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
(Date:12/1/2015)... December 1, 2015 Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of ...
Breaking Medicine Technology: